Mostrar el registro sencillo del ítem
The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine
dc.contributor.author | Labella, Marina | |
dc.contributor.author | Céspedes Lagos, José Antonio | |
dc.contributor.author | Doña, Inmaculada | |
dc.contributor.author | Shamji, Mohamed H. | |
dc.contributor.author | Agache, Ioana | |
dc.contributor.author | Mayorga Mayorga, Cristobalina | |
dc.contributor.author | Torres-Jaén, María Josefa | |
dc.date.accessioned | 2022-05-09T06:33:53Z | |
dc.date.available | 2022-05-09T06:33:53Z | |
dc.date.issued | 2021-10-24 | |
dc.identifier.citation | Labella M, Céspedes JA, Doña I, et al. The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine. Allergy. 2021;00:1– 13. https://doi.org/10.1111/all.15148 | es_ES |
dc.identifier.uri | https://hdl.handle.net/10630/24066 | |
dc.description.sponsorship | The present study has been supported by the Institute of Health ‘Carlos III’ (ISCIII) of the Ministry of Economy and Competitiveness (grants co-funded by European Regional Development Fund (ERDF): PI18/00095, RETICS ARADYAL RD16/0006/0001; Andalusian Regional Ministry Health (PE-0172- 2018). ML is supported by the ‘Río Hortega’ program [CM20/00210] from the ISCIII. CM holds a ‘Nicolas Monardes’ research contract (RC- 0004- 2021) and ID holds an SAS Stabilization contract (ref B-0001- 2017) by Andalusian Regional Ministry Health. Funding for open access charge: Universidad de Málaga / CBUA | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | COVID-19 | es_ES |
dc.subject.other | Allergic reactions | es_ES |
dc.subject.other | Basophil activation test | es_ES |
dc.subject.other | BNT162b2 | es_ES |
dc.subject.other | Vaccines | es_ES |
dc.title | The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.centro | Facultad de Medicina | es_ES |
dc.identifier.doi | https://doi.org/10.1111/all.15148 | |
dc.rights.cc | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |